Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
IKIkena Oncology, Inc. logo

Ikena Oncology, Inc. (IKNA)

NASDAQ Global Market · Currency in USD
$17.16 ▲ +15.79 (+1,152.55%)
At close: Jul 25, 4:00 PM ET. Market closed.
$1.46 ▼ -15.70 (-91.49%)
After hours: Jul 25, 7:47 PM ET

Summary

Previous Close
$1.37
Open
$1.38
Day's Range
$1.36 – $17.16
52 Week Range
$1.36 – $23.28
Volume
457,262
Avg. Volume
18,002
Market Cap
$718.82M
Beta (5Y Monthly)
0.50
PE Ratio (TTM)
--
EPS (TTM)
-$3.74
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$1.33

Profile: Ikena Oncology, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
10
CEO
Mark Manfredi

Ikena Oncology, Inc. is a biopharmaceutical company specializing in precision oncology. Its primary objective is to create therapeutic agents specifically formulated for patient populations identified through biomarkers, thereby addressing significant unmet medical needs. The company's leading drug candidate is IK-930, an orally administered small molecule designed to inhibit the transcriptional enhanced associate domain (TEAD) transcription factor, a key component of the Hippo signaling pathway.

Earnings

DateEst.Actual
Nov 6, 2025-$0.13-$0.53Miss
Jul 24, 2025-$0.14-$0.06Beat
May 8, 2025-$0.21-$0.18Beat
Mar 6, 2025-$0.19-$0.18Beat
Nov 7, 2024-$0.27-$0.19Beat
Aug 8, 2024-$0.31-$0.27Beat

Analyst view

Consensus price target
$1.33 ▼ -92.2%
Range $1.33 – $1.33
Rating: Buy
Buy 80% · Hold 20% · Sell 0%

Get free alerts on IKNA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.